arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Sagimet Biosciences Inc.

SGMT Health Care Biotechnology: Pharmaceutical Preparations
$9.58
▼ -4.1% Today
as of Oct 23, 16:06 ET
Last 30 days -11.95% Sep 14 → Oct 23
$7.26 $8.31 $9.36 $10.41 $11.46 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$10.00
High
$10.15
Low
$9.63
Volume
$1M
Avg Vol
$1M
Mkt Cap
$577M
P/E (TTM)
—
Beta
—
52w High
$11.45
52w Low
$4.50
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 24 items

Oct 23 · 00:10 PR PR Newswire
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
Oct 22 · 13:30 MT Newswires
Sagimet Biosciences Doses First Patient in US Phase 3 Trial of Denifanstat to Treat Acne
Oct 22 · 11:00 PR GlobeNewswire
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
▸ Show all 24 press releases & news Free account →

SGMT earnings at a glance

The options market is pricing a move of about ±25.8% after the report, a range of roughly $7.11 to $12.05 from today's $9.58. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±2.4% on average; after the most recent report on May 12, 2026 it moved -0.5%. That means options currently expect more movement than SGMT has typically delivered. SGMT beat the consensus EPS estimate in 4 of its last 4 reported quarters. Implied volatility is currently 218%. The share price of $9.58 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$4.50
$11
73% of range
Avg surprise (last 4)
+21.3%
Avg reaction (last 2)
-2.4%
0% positive
Latest IV / EM
218%
EM ±25.8% · $10 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-35.80$-26.91$-18.01$-9.12$-0.23 Actual $-35.58Actual $-35.80Actual $-0.35Actual $-0.23Actual $-0.25Actual $-0.45Actual $-0.56Est $-0.79Actual $-0.32Est $-0.52Actual $-0.40Est $-0.41Actual $-0.33Est $-0.39Actual $-0.26 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-18M$-16M$-15M$-13M$-11M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.26 — — — — financials
Tue May 12, 2026Mar/2026 $-0.33 $-0.39 +15.4% +41.1% -0.5% earnings
Thu Nov 13, 2025Sep/2025 $-0.40 $-0.41 +2.4% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.32 $-0.52 +38.5% — — earnings
Thu May 8, 2025Mar/2025 $-0.56 $-0.79 +29.1% — -4.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.45 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.25 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.23 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.35 — — — — financials
Fri Jun 30, 2023Jun 2023 $-35.80 — — — — financials
Fri Mar 31, 2023Mar 2023 $-35.58 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-16M$-12M—$-14M$-12M$-20M—$-17M
Net income$-14M$-11M—$-13M$-10M$-18M—$-15M
EPS (diluted)$-0.26$-0.33—$-0.40$-0.32$-0.56—$-0.45

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$166M$37M$35M$32M$42M$65M$76M$77M
Inventory————————
Total current assets$244M$108M$116M$119M$127M$146M$153M$157M
Total assets$263M$108M$116M$128M$137M$146M$160M$175M
Long-term debt————————
Total liabilities$7M—$5M——$7M$4M$4M
Total equity$256M$102M$111M$119M$130M$139M$156M$171M

Implied volatility — last 90 days

64%311%558%804%1051% Jun 07 — IV 147% · EM ±20.3%Jun 08 — IV 162% · EM ±21.4%Jun 09 — IV 150% · EM ±18.8%Jun 10 — IV 153% · EM ±18.1%Jun 11 — IV 165% · EM ±18.3%Jun 12 — IV 287% · EM ±29.3%Jun 15 — IV 481% · EM ±34.8%Jun 16 — IV 591% · EM ±34.9%Jun 17 — IV 586% · EM ±24.5%Jun 19 — IV 98% · EM ±21.7%Jun 22 — IV 91% · EM ±19.0%Jun 23 — IV 83% · EM ±17.0%Jun 24 — IV 94% · EM ±18.8%Jun 25 — IV 93% · EM ±18.2%Jun 26 — IV 83% · EM ±15.9%Jun 29 — IV 238% · EM ±42.1%Jun 30 — IV 83% · EM ±14.2%Jul 01 — IV 84% · EM ±14.1%Jul 02 — IV 89% · EM ±14.5%Jul 03 — IV 92% · EM ±14.5%Jul 06 — IV 89% · EM ±12.3%Jul 07 — IV 113% · EM ±15.0%Jul 08 — IV 94% · EM ±11.8%Jul 09 — IV 86% · EM ±10.2%Jul 10 — IV 86% · EM ±9.5%Jul 13 — IV 126% · EM ±10.5%Jul 14 — IV 116% · EM ±8.4%Jul 15 — IV 154% · EM ±9.1%Jul 16 — IV 123% · EM ±5.2%Jul 20 — IV 95% · EM ±22.3%Jul 21 — IV 99% · EM ±23.0%Jul 22 — IV 96% · EM ±22.0%Jul 23 — IV 95% · EM ±21.4%Jul 24 — IV 98% · EM ±21.6%Jul 27 — IV 98% · EM ±20.5%Jul 28 — IV 101% · EM ±20.6%Jul 29 — IV 103% · EM ±20.6%Jul 30 — IV 98% · EM ±19.2%Jul 31 — IV 129% · EM ±24.6%Aug 03 — IV 103% · EM ±18.2%Aug 04 — IV 89% · EM ±15.4%Aug 05 — IV 121% · EM ±20.3%Aug 06 — IV 124% · EM ±20.0%Aug 07 — IV 113% · EM ±17.7%Aug 10 — IV 108% · EM ±14.9%Aug 11 — IV 95% · EM ±12.6%Aug 12 — IV 116% · EM ±14.5%Aug 13 — IV 121% · EM ±14.3%Aug 14 — IV 111% · EM ±12.2%Aug 17 — IV 92% · EM ±7.7%Aug 18 — IV 160% · EM ±11.6%Aug 19 — IV 124% · EM ±7.3%Aug 20 — IV 136% · EM ±5.7%Aug 24 — IV 70% · EM ±14.7%Aug 25 — IV 71% · EM ±14.6%Aug 26 — IV 80% · EM ±16.1%Aug 27 — IV 75% · EM ±14.7%Aug 28 — IV 64% · EM ±12.3%Aug 31 — IV 72% · EM ±12.7%Sep 01 — IV 75% · EM ±12.9%Sep 02 — IV 81% · EM ±13.5%Sep 03 — IV 133% · EM ±21.5%Sep 04 — IV 82% · EM ±12.8%Sep 07 — IV 92% · EM ±12.8%Sep 08 — IV 87% · EM ±11.4%Sep 09 — IV 91% · EM ±11.4%Sep 10 — IV 113% · EM ±13.3%Sep 11 — IV 100% · EM ±11.0%Sep 14 — IV 218% · EM ±18.2%Sep 15 — IV 159% · EM ±11.5%Sep 16 — IV 178% · EM ±10.5%Sep 17 — IV 1052% · EM ±43.9%Sep 21 — IV 79% · EM ±16.4%Sep 22 — IV 85% · EM ±17.4%Sep 23 — IV 83% · EM ±16.6%Sep 24 — IV 87% · EM ±17.0%Sep 25 — IV 93% · EM ±17.9%Sep 28 — IV 78% · EM ±13.8%Sep 29 — IV 84% · EM ±14.5%Sep 30 — IV 71% · EM ±11.9%Oct 01 — IV 84% · EM ±13.6%Oct 02 — IV 146% · EM ±22.8%Oct 06 — IV 119% · EM ±15.7%Oct 07 — IV 148% · EM ±18.6%Oct 08 — IV 218% · EM ±25.8%

Sector peers

STTK
Shattuck Labs, Inc.
$568M $5.49-1.6%
CTMX
CytomX Therapeutics, Inc.
$556M $2.32-3.3%
CLYM
Climb Bio, Inc.
$615M $10.19-6.3%
IRWD
Ironwood Pharmaceuticals, Inc.
$621M $3.46-2.5%
CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
OCS
Oculis Holding AG
$508M $7.90+0.4%

SGMT earnings FAQ

What is SGMT's expected move for earnings?

Options currently price a move of about ±25.8%, or $2.47 per share either way from $9.58.

How does SGMT stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.4%, up 0 times and down 2 times.

What is SGMT's implied volatility?

SGMT's at-the-money implied volatility is about 218% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in